BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2025 9:23:02 AM | Browse: 291 | Download: 668
Publication Name World Journal of Clinical Oncology
Manuscript ID 104959
Country United States
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy
Manuscript Source Invited Manuscript
All Author List Wenxue Ma and Natalia Baran
ORCID
Author(s) ORCID Number
Wenxue Ma http://orcid.org/0000-0001-9228-6162
Natalia Baran http://orcid.org/0000-0003-0618-4798
Funding Agency and Grant Number
Funding Agency Grant Number
National Science Centre, Poland 2021/43/B/NZ5/03345
Corresponding Author Wenxue Ma, MD, PhD, Professor, Department of Medicine, Sanford Stem Cell Institute, and Moores Cancer Center, University of California San Diego, 2880 Torrey Pines Scenic Drive, San Diego, CA 92093, United States. wma@health.ucsd.edu
Key Words Esophageal squamous cell carcinoma; Chemoimmunotherapy, Radiotherapy; Immune checkpoint inhibitors; Locally advanced cancer; Treatment outcomes
Core Tip This editorial highlights the study by Wei et al, which examines the impact of induction chemoimmunotherapy followed by radiotherapy or concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). The study demonstrates improved survival outcomes and a manageable safety profile, identifying the effectiveness of induction therapy and maintenance immunotherapy as key prognostic factors. This innovative approach represents a promising advancement in the treatment of ESCC and underscores the need for future prospective trials and mechanistic studies incorporating biomarker investigations to refine therapeutic strategies and enhance patient outcomes.
Publish Date 2025-07-22 09:23
Citation

Ma W, Baran N. Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy. World J Clin Oncol 2025; 16(7): 104959

URL https://www.wjgnet.com/2218-4333/full/v16/i7/104959.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i7.104959
Full Article (PDF) WJCO-16-104959-with-cover.pdf